Literature DB >> 6344430

Functional antibacterial activity of a human intravenous immunoglobulin preparation: in vitro and in vivo studies.

G W Fischer, K W Hunter, V G Hemming, S R Wilson.   

Abstract

The functional antibacterial activity of an intravenous immunoglobulin preparation (Swiss Red Cross Immunoglobulin, SRK-Ig) was tested both in vitro and in vivo. Using type III group B streptococci as a model system, the intravenous immunoglobulin preparation was shown to enhance phagocytosis and killing of the bacteria by human neutrophils. There was good activity to several type III strains, and for efficient opsonization both antibody and complement were required. In an animal model of neonatal group B streptococcal sepsis, passively administered immunoglobulin enhanced survival with 27/37 (73%) treated animals surviving compared to only 3/16 (19%) controls. These studies demonstrate that the intravenous immunoglobulin preparation SRK-Ig has retained functional activity and may have potential value for prophylaxis or therapy of certain bacteria infections.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6344430     DOI: 10.1111/j.1423-0410.1983.tb04485.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  6 in total

Review 1.  Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases.

Authors:  V G Hemming
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

Review 2.  Immunoglobulin therapy for neonatal sepsis: an overview of animal and clinical studies.

Authors:  G W Fischer
Journal:  J Clin Immunol       Date:  1990-11       Impact factor: 8.317

3.  Haemophilus influenzae type b opsonins of intravenous immunoglobulins.

Authors:  S Bender; S Hetherington
Journal:  J Clin Immunol       Date:  1987-11       Impact factor: 8.317

Review 4.  Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies.

Authors:  Kathleen E Sullivan; Hamid Bassiri; Ahmed A Bousfiha; Beatriz T Costa-Carvalho; Alexandra F Freeman; David Hagin; Yu L Lau; Michail S Lionakis; Ileana Moreira; Jorge A Pinto; M Isabel de Moraes-Pinto; Amit Rawat; Shereen M Reda; Saul Oswaldo Lugo Reyes; Mikko Seppänen; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2017-08-07       Impact factor: 8.317

Review 5.  Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock.

Authors:  Marissa M Alejandria; Mary Ann D Lansang; Leonila F Dans; Jacinto Blas Mantaring
Journal:  Cochrane Database Syst Rev       Date:  2013-09-16

6.  Low Rates of Poliovirus Antibodies in Primary Immunodeficiency Patients on Regular Intravenous Immunoglobulin Treatment.

Authors:  Beatriz T Costa-Carvalho; Kathleen E Sullivan; Patrícia M Fontes; Fernanda Aimé-Nobre; Isabela G S Gonzales; Elaine S Lima; Celso Granato; Maria Isabel de Moraes-Pinto
Journal:  J Clin Immunol       Date:  2018-07-14       Impact factor: 8.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.